Addendum: Systemic AL amyloidosis: current approach and future direction

PDF  |  How to cite

Oncotarget. 2023; 14:721-721. https://doi.org/10.18632/oncotarget.28478

Metrics: PDF 600 views  |   ?  

Maroun Bou Zerdan1, Lewis Nasr2, Farhan Khalid3, Sabine Allam4, Youssef Bouferraa5, Saba Batool6, Muhammad Tayyeb7, Shubham Adroja8, Mahinbanu Mammadii1, Faiz Anwer9, Shahzad Raza9 and Chakra P. Chaulagain10

1Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA
2University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA
4Department of Medicine and Medical Sciences, University of Balamand, Balamand, Lebanon
5Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
6Department of Internal Medicine, UnityPoint Methodist, Peoria, IL 61636, USA
7Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA
8Hematology and Medical Oncology, Houston Methodist Cancer Center, Houston, TX 77094, USA
9Department of Hematology-Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
10Department of Hematology-Oncology, Myeloma and Amyloidosis Program, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA

Published: July 20, 2023

Copyright: © 2023 Bou Zerdan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Research funding was obtained from the Cleveland Clinic Florida, Maroone Cancer Center, Malignant Hematology Research Fund.

Original article: Oncotarget. 2023; 14:384-394. DOI: https://doi.org/10.18632/oncotarget.28415.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28478